RecruitMe Clinical Trial

DIV-NB-401: A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin (Dinutuximab, monocolonal antibody ch14.18) in High-Risk Neuroblastoma Patients
A study for children with high-risk neuroblastoma using study drug unituxin
Sponsor:United Therapeutics Corp.
Enrolling:Male and Female Patients
Maximum Age:17 years old
IRB Number:AAAQ6521
Contact: Alice Lee: 212-305-5808 / al2041@cumc.columbia.edu
Additional Study Information:

The purpose of this research study is to collect information about the percentage of people that develop HACA when they are treated with Unituxin and determine if HACA affects the blood levels of Unituxin. Unituxin is a type of antibody. Antibodies are made by the body to attack tumors and fight infections. Unituxin is a chimeric antibody which means it is made in the lab using cells from both mice and humans. Unituxin reacts with a substance (GD2) made by neuroblastoma cancer cells. By attaching to GD2, Unituxin helps your bodys immune system find and attack the cancer. Sometimes people who receive drugs made with cells from a mouse develop an antibody to them, called human anti-chimeric antibody (HACA). High levels of HACA can change the amount of Unituxin in your blood.

This study is closed
Investigator
Alice Lee, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Alice Lee
Email: al2041@cumc.columbia.edu
Phone: 212-305-5808